Aarti Pharmalabs Limited has informed the Exchange that Board of Directors at its meeting held on May 10, 2025, recommended Final Dividend of Rs. 2.50 per equity share.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs announced audited FY25 results with strong growth. Standalone revenue rose 17.9% to Rs. 1,77,135 lakhs (vs Rs. 1,50,213 lakhs in FY24), while standalone PAT jumped 28.3% to Rs. 25,735 lakhs (vs Rs. 20,065 lakhs). Consolidated revenue grew 14.2% to Rs. 2,11,507 lakhs with PAT up 25.6% at Rs. 27,240 lakhs. Q4 standalone revenue grew 27.7% YoY to Rs. 52,962 lakhs, with PAT up 41% to Rs. 8,885 lakhs. The Board recommended a final dividend of Rs. 2.50 per share (50% on Rs. 5 face value), subject to shareholder approval. Statutory auditors issued an un-modified opinion on both standalone and consolidated financials.
Strong double-digit profit growth driven by healthy revenue expansion and improving margins is positive for shareholders. The Rs. 2.50 dividend (50% payout) signals management confidence in cash flows, though dividend yield is modest. Overall, the results should be viewed favorably by the market.